Organized and sponsored by the Rare Earth Office under the State Planning Committee and The Chinese Society of Rare Earths, the monograph "Rare Earth" was recently published by the Chinese Metallurgy Press. ...Organized and sponsored by the Rare Earth Office under the State Planning Committee and The Chinese Society of Rare Earths, the monograph "Rare Earth" was recently published by the Chinese Metallurgy Press. The monograph is a contribution of over 100 named rare earth specialists from Beijing University, Tsinghua University, General Corpora-展开更多
基于亚马逊平台热销中医专著Between Heaven and Earth:A Guide to Chinese Medicine (《天地之间:中医指南》),举例分析其巧用“取象比类”思维、借用现代医学术语、采用图示辅助理解、创新中医文化表达的4种译写策略,并借助调查问卷...基于亚马逊平台热销中医专著Between Heaven and Earth:A Guide to Chinese Medicine (《天地之间:中医指南》),举例分析其巧用“取象比类”思维、借用现代医学术语、采用图示辅助理解、创新中医文化表达的4种译写策略,并借助调查问卷佐证这4种译写策略的有效性与可取性,希望通过借鉴学习“他塑”,完善中医国际形象的“自塑”。同时检查“他塑”出现的文化误读,反观“自塑”的不足,从而调整中医传播策略,促进中医药文化的海外传播。展开更多
According to the drug-related risk factors indicated in the latest product monograph, we made this research to analyze and discuss the risk factors associated with rosiglitazone in clinical application in China-Japan ...According to the drug-related risk factors indicated in the latest product monograph, we made this research to analyze and discuss the risk factors associated with rosiglitazone in clinical application in China-Japan Friendship Hospital. We collected and reviewed all cases involving inpatients who had used rosiglitazone in the hospital over the past two years. The focus of our study is on the identification and discussion of the incidence of adverse reactions, contraindications and drug induced problems associ- ated with monotherapy or combined therapy of rosiglitazone. Three hundred and ninety eight cases were reviewed in the study including 3 patients with type 1 DM （0.75%） and 395 patients with type 2 diabetes mellitus （99.25%）. Peripheral edema developed in 9 patients （2.26%） in the course of rosiglitazone therapy; one patient （0.25%） was found to have macula edema before rosiglitazone therapy; Cardiac abnormalities were identified in 6 patients （1.51%） in the course of treatment, of which 2 patients were NYHA class 1, 3 patients were NYHA class Ⅱ and 1 patient was NYHA class IV. Abnormal hepatic function （elevated ALT） was found in 79 patients （19.85%） during their stay in hospital. In these patients, ALT levels of 1 - 2.5 times, 2.5 - 3 times over the upper limit were identified in 70 patients, 3 patients and 6 patients, respectively. Of the 398 patients on rosiglitazone, 123 patients （30.90%）, 165 patients （41.46%）, 104 patients （26.13%）, 3 patients （0.75%） and 1 patient （0.25%） were found to use concurrently insulin, metformin, organic nitrate, gemfibrozil and rifampin, respectively. We analyzed the risk factors associated with the clinical use of rosiglitazone, and identified the potential risks, and put forward suggestions to improve the effectiveness and safety of rosiglitazone therapy.展开更多
文摘Organized and sponsored by the Rare Earth Office under the State Planning Committee and The Chinese Society of Rare Earths, the monograph "Rare Earth" was recently published by the Chinese Metallurgy Press. The monograph is a contribution of over 100 named rare earth specialists from Beijing University, Tsinghua University, General Corpora-
文摘基于亚马逊平台热销中医专著Between Heaven and Earth:A Guide to Chinese Medicine (《天地之间:中医指南》),举例分析其巧用“取象比类”思维、借用现代医学术语、采用图示辅助理解、创新中医文化表达的4种译写策略,并借助调查问卷佐证这4种译写策略的有效性与可取性,希望通过借鉴学习“他塑”,完善中医国际形象的“自塑”。同时检查“他塑”出现的文化误读,反观“自塑”的不足,从而调整中医传播策略,促进中医药文化的海外传播。
文摘According to the drug-related risk factors indicated in the latest product monograph, we made this research to analyze and discuss the risk factors associated with rosiglitazone in clinical application in China-Japan Friendship Hospital. We collected and reviewed all cases involving inpatients who had used rosiglitazone in the hospital over the past two years. The focus of our study is on the identification and discussion of the incidence of adverse reactions, contraindications and drug induced problems associ- ated with monotherapy or combined therapy of rosiglitazone. Three hundred and ninety eight cases were reviewed in the study including 3 patients with type 1 DM （0.75%） and 395 patients with type 2 diabetes mellitus （99.25%）. Peripheral edema developed in 9 patients （2.26%） in the course of rosiglitazone therapy; one patient （0.25%） was found to have macula edema before rosiglitazone therapy; Cardiac abnormalities were identified in 6 patients （1.51%） in the course of treatment, of which 2 patients were NYHA class 1, 3 patients were NYHA class Ⅱ and 1 patient was NYHA class IV. Abnormal hepatic function （elevated ALT） was found in 79 patients （19.85%） during their stay in hospital. In these patients, ALT levels of 1 - 2.5 times, 2.5 - 3 times over the upper limit were identified in 70 patients, 3 patients and 6 patients, respectively. Of the 398 patients on rosiglitazone, 123 patients （30.90%）, 165 patients （41.46%）, 104 patients （26.13%）, 3 patients （0.75%） and 1 patient （0.25%） were found to use concurrently insulin, metformin, organic nitrate, gemfibrozil and rifampin, respectively. We analyzed the risk factors associated with the clinical use of rosiglitazone, and identified the potential risks, and put forward suggestions to improve the effectiveness and safety of rosiglitazone therapy.
